Some breast cancers mayregress spontaneously
Unexpected findings from a study ofNorwegian women who have and have notreceived routine biennial screening mammographysuggest some breast cancers mayspontaneously regress.
Unexpected findings from a study of Norwegian women who have and have not received routine biennial screening mammography suggest some breast cancers may spontaneously regress.
Dr. Per-Henrik Zahl, a senior statistician at the Norwegian Institute of Public Health in Oslo, and colleagues compared cumulative breast cancer incidence in agematched cohorts of women before and after the initiation of biennial mammography.
The initiation of screening mammography has been associated with increased breast cancer incidence among women of screening age, the researchers said. If all the newly detected cancers progressed and became clinically evident as women age, a fall in incidence among older women should follow, but such was not the case in this study. Results were reported in the Nov. 24 issue of the Archives of Internal Medicine (2008;168[21]:2311-2316).
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
